Pfizer Inc submits new paediatric data for Lipitor to EMEA

Posted on: Wed, 18 Nov 2009 06:08:00 EST


Symbols: PFE
Nov 18, 2009 (M2 EQUITYBITES via COMTEX) --
PFE | Quote | Chart | News | PowerRating -- Health care company Pfizer Inc (NYSE:PFE) declared on Wednesday the
submission of paediatric data for Lipitor (atorvastatin) to the
European Medicines Agency (EMEA).

This follows the EMEA's conclusion that Pfizer's programme studying the
use of Lipitor in children with high cholesterol is in compliance with
its requirements.

Pfizer has also developed a new chewable form of Lipitor, including a
paediatric-appropriate 5 mg dose, which is part of this submission.

The company will be eligible and plans to apply for an additional six
months of patent/supplementary protection certificate protection for
Lipitor in certain European Union countries if it fulfils all further
requirements of the EU Paediatric Medicines Regulation.

According to Pfizer, approximately one in 500 people suffer from an
inherited disorder called Familial Hypercholesterolemia (FH) which
causes high levels of LDL-cholesterol ("bad" cholesterol) and an
increased risk of heart disease.

Comments on this story may be sent to admin@m2.com

For full details on Pfizer Inc (PFE) PFE. Pfizer Inc (PFE) has Short Term PowerRatings at TradingMarkets. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.